How JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017
In 4Q17, Johnson & Johnson’s (JNJ) hip medical devices business generated revenue of $364 million.
In 2017, Johnson & Johnson’s (JNJ) Advanced Surgical Devices segment reported revenue of $3.8 billion.
In 4Q17, Johnson & Johnson’s (JNJ) Vision Care segment generated revenue of $1.1 billion.
In 4Q17, Johnson & Johnson’s (JNJ) Medical Devices segment generated revenue of $6.9 billion.
In 4Q17, Boston Scientific’s (BSX) Cardiovascular business segment reported sales of $913 million.
In 4Q17, Boston Scientific’s (BSX) Cardiovascular business registered strong YoY (year-over-year) sales growth of ~8.7% on a reported basis.
In 4Q17, Boston Scientific’s (BSX) MedSurg segment witnessed double-digit YoY (year-over-year) growth of ~14.2%, on a reported basis.
Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.
BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.
On February 1, 2018, Boston Scientific (BSX) announced its 4Q17 and 2017 earnings results.
On January 24, 2018, Boston Scientific (BSX) announced an investment deal, including an acquisition option, with Millipede.
Boston Scientific (BSX) has spent ~$89 million on the settlement of lawsuits related mainly to its mesh litigation.
In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform.
BSX’s Lotus TAVR (transcatheter aortic valve replacement) system helped it enter the attractive TAVR market space with exceptional opportunity for growth.
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
In 4Q17, Boston Scientific’s (BSX) Rhythm Management segment registered sales of ~$565 million.
Medtronic (MDT) plans to release its 3Q18 earnings results on February 20, 2018.
On February 20, 2018, Medtronic (MDT) is set to announce its 3Q18 earnings results.
Medtronic (MDT) plans to announce its 3Q18 earnings results on February 20.
As of February 12, 2018, according to a Reuters survey consisting of 19 investment research firms, 63% of analysts recommended BD as a “buy,” and 37% rate it as a “hold.”